Presentations

Date	Documents
June 2026	22 June 2026 Investor Presentation

Date	Documents
November 7, 2026	1060: Leveraging multispecific antibody-like molecules to localize CD40 agonism to the tumor to overcome the immunosuppressive microenvironment and potentiate anti-tumor immunity

Date	Documents
June 22, 2026	A Breakthrough in Fighting Solid Tumors with a Novel Trispecific, APVO451, Targeting Nectin-4, CD3 and CD40 to Overcome the Immunosuppressive Tumor Microenvironment

Date	Documents
December 8, 2025	A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIR™ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy

Date	Documents
November 8, 2024	673: Preliminary results from a phase I dose escalation study of ALG.APV-527, a 5T4 x 4-1BB bispecific antibody, in patients with advanced solid tumors demonstrate favorable safety and biological activity

Date	Documents
September 14, 2024	First-in-Human Phase I Dose Escalation Study of ALG.APV-527, a 5T4 Tumor Antigen-Conditional 4-1BB Bispecific Antibody, in Patients with Advanced Solid Tumors, Demonstrates Positive Safety, Signals of Biological Activity and Patients with Lasting Stable D

Date	Documents
December 11, 2022	Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Date	Documents
April 12, 2022	PSMA x CD3 targeted bispecific candidate designed to optimize T cell fitness and distribution to solid tumor

Date	Documents
December 13, 2021	Tolerabillity and Single Agent Anti-Neplastic Activity of the CD3xCD123 Bispecific Antibody APV0436 in Patients with Relapsed/Refractory AML or MDS
December 13, 2021	Risk and Severity of Cytokine Release Syndrome in-Patients with Relapsed/Refractory (R/R) AML or MDS Treated with CD3xDC123 Bispecific Antibody APV0436

Date	Documents
November 11, 2021	ALG.APV-527: A 5T4 tumor directed bispecific approach utilizing ADAPTIRTMplatform technology designed for conditional 4-1BB T cell / NK agonism against solid tumors
November 11, 2021	APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTMplatform technology designed to deliver a conditional T cell / NK response against solid tumors

Date	Documents
December 7, 2020	Preliminary Results from a Phase 1 Study of APVO436, a Novel Anti-CD123 x Anti-CD3 Bispecific Molecule, in Relapsed/Refracroty Acure Myeloid Leukemia and Myelodysplasctic Syndrome

Date	Documents
April 10, 2021	APVO603:A dual 4-1BB and Ox40 bispecific approach utilizing ADAPTIR platform technology designed to deliver a conditional T cell/NK response against solid tumors
November 9, 2020	APVO603 Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ Bispecific Antibody with Potential To Enhance Anti-Tumor Responses to Solid Tumors

Date	Documents
April 10, 2021	APVO442:A bispecific T ceel-engaging candidate utilizing the ADAPTIR-FLEX plaftform technology with unique properties designed for optimal tumor distribution and cytotoxic response against PSMA-expressing solid tumors

Date	Documents
April 2019	APVO436, a Bispecific anti-CD123 x anti-CD3 ADAPTIR™ Molecule for Redirected T-cell Cytotoxicity with Limited Cytokine Release, is Well Tolerated in Repeat Dose Toxicology Studies in Cynomolgus Macaques
April 2018	APVO436, a Bispecific anti-CD123 x anti-CD3 ADAPTIR™ Molecule for Redirected T-cell Cytotoxicity, Induces Potent T-cell Activation, Proliferation and Cytotoxicity with Limited Cytokine Release
December 2017	Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro
April 2017	Bispecific anti-CD123 x anti-CD3 ADAPTIR™ Molecules for Redirected T-cell Cytotoxicity in Hematological Malignancies

Date	Documents
November 2020	ALG.APV-527 Potent Tumor-directed T Cell Activation and in Vivo Tumor Inhibition Induced by a 4-1BB x 5T4 ADAPTIR Bispecific Antibody
November 2019	Potent and Tumor-directed T-cell Activation and Tumor Inhibition Inducted by a 4-1BB x 5T4 ADAPTIR® Bispecific Antibody
April 2019	Preclinical Safety and Efficacy of a Tumor-directed T-cell Activating 4-1BB x 5T4 ADAPTIR® Bispecific Antibody
May 2018	Tumor Antigen-dependent T Cell Activation and Tumor Localization Induced by a Novel 4-1BB X 5T4 ADAPTIR™ Bispecific Antibody
May 2018	Screening, Optimization and Characterization of a Novel 4-1BB x 5T4 ADAPTIR™ Bispecific Antibody
May 2018	Activation of the CD137 Pathway in T Cells by a CD137 X 5T4 Bispecific ADAPTIR™ Molecule Requires Co-engagement of CD137 and 5T4